{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T04:10:43Z","timestamp":1771992643617,"version":"3.50.1"},"reference-count":177,"publisher":"Elsevier","isbn-type":[{"value":"9780443192494","type":"print"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/bs.ircmb.2023.05.005","type":"book-chapter","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T07:39:22Z","timestamp":1688197162000},"page":"1-41","source":"Crossref","is-referenced-by-count":3,"title":["Viral vectors engineered for gene therapy"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.ircmb.2023.05.005_bib1","doi-asserted-by":"crossref","first-page":"12989","DOI":"10.1073\/pnas.95.22.12989","article-title":"Noncytopathic Sindbis virus RNA vectors for heterologous gene expression","volume":"95","author":"Agapov","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib2","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.3390\/ijms22126275","article-title":"Cell and gene therapy for anemia: Hematopoietic stem cells and gene editing","volume":"22","author":"Anurogo","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib3","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood.V95.3.820.003k32_820_828","article-title":"Sustained high\u2010level expression of full\u2010length human factor VIII and a restoration of clotting activity in hemophilic mice using a minimal adenovirus vector","volume":"95","author":"Balagu\u00e9","year":"2000","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.nmd.2018.06.009","article-title":"Personalized gene and cell therapy for Duchenne Muscular Dystrophy","volume":"28","author":"Barth\u00e9l\u00e9my","year":"2018","journal-title":"Neuromuscular Disorders"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.virol.2019.02.014","article-title":"Rapid establishment of stable retroviral packaging cells and recombinant susceptible target cell lines employing novel transposon vectors derived from Sleeping Beauty","volume":"531","author":"Berg","year":"2019","journal-title":"Virology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.actbio.2016.03.036","article-title":"Quantification of cellular and nuclear uptake rates of polymeric gene delivery nanoparticles and DNA plasmids via flow cytometry","volume":"37","author":"Bishop","year":"2016","journal-title":"Acta Biomaterialia"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0006-8993(00)02915-2","article-title":"Towards a neuroprotective gene therapy for Parkinson\u2019s disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model","volume":"886","author":"Bj\u00f6rklund","year":"2000","journal-title":"Brain Research"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-pharmtox-010715-103633","article-title":"RNA interference (RNAi)-based therapeutics: Delivering on the promise?","volume":"56","author":"Bobbin","year":"2016","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/387362","article-title":"Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas","author":"Boisgerault","year":"2013","journal-title":"BioMed Research International"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib10","doi-asserted-by":"crossref","first-page":"16363","DOI":"10.1073\/pnas.0904514106","article-title":"Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1\u2013AAT gene therapy","volume":"106","author":"Brantly","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib11","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1089\/hum.2013.071","article-title":"Transgene expression up to 7 years in nonhuman primates following hepatic transduction with helper-dependent adenoviral vectors","volume":"24","author":"Brunetti-Pierri","year":"2013","journal-title":"Human Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib12","unstructured":"Butterfield, R., Shieh, P., Geffen, D., Yong, F., Binks, M., McDonnell, T.G., Levy, D. (2023). One year data from ambulatory boys in a phase 1b, open\u2010label study of fordadistrogene movaparvovec (PF\u201006939926) for Duchenne muscular dystrophy (DMD). MDA Conference, Poster 53. \u3008www.mdaconference.org\/abstract-library\/one-year-data-from-ambulatory-boys-in-a-phase-1b-open-label-study-of-fordadistrogene-movaparvovec-pf-06939926-for-duchenne-muscular-dystrophy-dmd\/\u3009."},{"key":"10.1016\/bs.ircmb.2023.05.005_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151800","article-title":"Successful phenotype improvement following gene therapy for severe hemophilia A in privately owned dogs","volume":"11","author":"Callan","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/d41586-020-02386-2","article-title":"Russia\u2019s fast-track coronavirus vaccine draws outrage over safety","volume":"584","author":"Callaway","year":"2020","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa1405","article-title":"Liver-directed lentiviral gene therapy in a dog model of hemophilia B","volume":"7","author":"Cantore","year":"2015","journal-title":"Science Translational Medicine"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib16","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib17","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1089\/hum.2018.122","article-title":"Gene therapy for hemoglobinopathies","volume":"29","author":"Cavazzana","year":"2018","journal-title":"Human Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib18","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)\u2010X1 disease","volume":"28","author":"Cavazzana-Calvo","year":"2000","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib19","series-title":"ATMP Office of EMA","article-title":"Personal communication: mRNA drugs regulation and categorization","author":"Celis","year":"2022"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib20","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.ymthe.2017.02.019","article-title":"Progress toward gene therapy for Duchenne muscular dystrophy","volume":"25","author":"Chamberlain","year":"2017","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib21","doi-asserted-by":"crossref","first-page":"11634","DOI":"10.1128\/JVI.00996-07","article-title":"A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques","volume":"81","author":"Chen","year":"2007","journal-title":"Journal of Virology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1\u20132 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib23","first-page":"69","article-title":"Reovirus in cancer therapy: An evidence-based review","volume":"3","author":"Clements","year":"2014","journal-title":"Oncolytic Virotherapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad9784","article-title":"Phase I trial of vocimagine amiroretrorepvec and 5\u2013fluorocytosine for recurrent high\u2010grade glioma","volume":"8","author":"Cloughesy","year":"2016","journal-title":"Science Translational Medicine"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib25","first-page":"658","article-title":"Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung","volume":"3","author":"Conrad","year":"1996","journal-title":"Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib26","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ebiom.2016.11.016","article-title":"Phase 2a randomized clinical trial: Safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration","volume":"14","author":"Constable","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.88730","article-title":"Lentiviral-mediated phenotypic correction of cystic fibrosis pigs","volume":"1","author":"Cooney","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.cgt.7700987","article-title":"Replication-deficient rSV40 mediate pancreatic gene transfer and long-term inhibition of tumor growth","volume":"14","author":"Cordelier","year":"2007","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib29","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2014-07-588194","article-title":"AAV liver expression of FIXPadua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice","volume":"125","author":"Crudele","year":"2015","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib30","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1073\/pnas.92.5.1401","article-title":"Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows long\u2010term expression","volume":"92","author":"Dai","year":"1995","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib31","first-page":"442","article-title":"Adeno-associated virus integration","volume":"11","author":"Deyle","year":"2009","journal-title":"Current Opinion in Molecular Therapeutics"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib32","doi-asserted-by":"crossref","first-page":"18060","DOI":"10.1074\/jbc.273.29.18060","article-title":"Rapid, high level protein production using DNA-based Semliki Forest virus vectors","volume":"273","author":"DiCiommo","year":"1998","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib33","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1158\/1078-0432.CCR-06-2202","article-title":"A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses","volume":"13","author":"Durso","year":"2017","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib34","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","article-title":"Results from a phase I safety trial of hAADC gene therapy for Parkinson disease","volume":"270","author":"Eberling","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2174\/156652305774329285","article-title":"HSV-1 derived recombinant and amplicon vectors for gene transfer and gene therapy","volume":"5","author":"Epstein","year":"2005","journal-title":"Current Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib36","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","article-title":"AAV5\u2013miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in Huntington\u2019s disease minipig model","volume":"26","author":"Evers","year":"2018","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib37","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1089\/hum.1995.6.8-1039","article-title":"Gene therapy for hemophilia B: Host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression","volume":"6","author":"Fang","year":"1995","journal-title":"Human Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/biot.202000017","article-title":"Progress and perspectives in the development of lentiviral vector producer cells","volume":"16","author":"Ferreira","year":"2021","journal-title":"Biotechnology Journal"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib39","first-page":"165","article-title":"Recombinant rhabdoviruses: Vectors for vaccine development and gene therapy","volume":"292","author":"Finke","year":"2005","journal-title":"Current Topics in Microbiology and Immunology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib40","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190607","article-title":"Gene therapy for severe combined immunodeficiencies and beyond","volume":"217","author":"Fischer","year":"2020","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib41","doi-asserted-by":"crossref","first-page":"10613","DOI":"10.1073\/pnas.90.22.10613","article-title":"Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector","volume":"90","author":"Flotte","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib42","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1089\/hum.2011.053","article-title":"Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1\u2013antitrypsin: Interim results","volume":"22","author":"Flotte","year":"2011","journal-title":"Human Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib43","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ymthe.2006.04.008","article-title":"A dose-ranging study of AAV-hAADCtherapy in Parkinsonian monkeys","volume":"14","author":"Forsayeth","year":"2006","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib44","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","article-title":"Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer","volume":"70","author":"Galanis","year":"2010","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib45","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1055\/s-0037-1613761","article-title":"Structural basis for hemophilia A caused by mutations in the C domains of blood coagulation factor VIII","volume":"83","author":"Gale","year":"2000","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib46","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1158\/0008-5472.CAN-11-3898","article-title":"Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy","volume":"72","author":"Gan","year":"2012","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.virusres.2014.02.016","article-title":"Newcastle disease virus: Current status and our understanding","volume":"184","author":"Ganar","year":"2014","journal-title":"Virus Research"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib48","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(04)17590-9","article-title":"Gene therapy of X\u2010linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector","volume":"364","author":"Gaspar","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib49","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.1128\/JVI.77.16.8924-8933.2003","article-title":"Incorporation of tick-borne encephalitis virus replicons into virus-like particles by a packaging cell line","volume":"77","author":"Gherke","year":"2003","journal-title":"Journal of Virology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib50","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10863-005-9474-z","article-title":"SERCA2a in heart failure: Role and therapeutic prospects","volume":"37","author":"Gianni","year":"2005","journal-title":"Journal of Bioenergetics and Biomembranes"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib51","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221149781","article-title":"Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy","volume":"16","author":"Goedeker","year":"2023","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib52","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10637-009-9279-8","article-title":"Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with solid tumors","volume":"28","author":"Gollamudi","year":"2010","journal-title":"Investigational New Drugs"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib53","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nm1439","article-title":"rAAV6\u2013microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice","volume":"12","author":"Gregorevic","year":"2006","journal-title":"Nature Medicine"},{"issue":"9","key":"10.1016\/bs.ircmb.2023.05.005_bib54","doi-asserted-by":"crossref","first-page":"1012497","DOI":"10.3389\/fmed.2022.1012497","article-title":"RNA-based drugs and regulation: Toward a necessary evolution of the definitions issued from the European Union legislation","volume":"2022","author":"Guerriaud","year":"2022","journal-title":"Frontiers in Medicine"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib55","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.ophtha.2017.05.016","article-title":"Gene therapy for Leder hereditary optic neuropathy: Low and medium-dose visual results","volume":"124","author":"Guy","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib56","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus\u2010mediated gene therapy of SCID\u2010X1","volume":"118","author":"Hacein\u2010Bey\u2010Abina","year":"2008","journal-title":"Journal\u00a0of Clinical Investigation"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib57","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1404588","article-title":"A modified \u03b3\u2010retrovirus vector for X\u2010linked severe combined immunodeficiency","volume":"371","author":"Hacein\u2010Bey\u2010Abina","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib58","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/mt.2011.68","article-title":"Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid","volume":"19","author":"Hadac","year":"2011","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib59","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/mt.2010.77","article-title":"SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells","volume":"18","author":"Hadri","year":"2010","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib60","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13339","article-title":"Rational engineering of adeno-associated virus capsid enhances human hepatocyte tropism and reduced immunogenicity","volume":"55","author":"Han","year":"2022","journal-title":"Cell Proliferation"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib61","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","article-title":"Intravitreous injection of AAV2\u2013sFLT01 in patients with advanced neovascular age-related macular degeneration: A phase I, open-label trial","volume":"390","author":"Heier","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib62","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib63","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib64","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/cncr.25741","article-title":"Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts","volume":"117","author":"Hingorani","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib65","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib66","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene abeparvovec first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib67","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1089\/hum.2014.100","article-title":"Intravenous administration of retroviral replicating vector, Toca 511, demonstrates efficacy in orthotopic immune-competent mouse glioma model","volume":"26","author":"Huang","year":"2015","journal-title":"Human Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib68","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/178792a0","article-title":"A specific chemical difference between the globins of normal human and sickle cell anemia hemoglobin","volume":"178","author":"Ingram","year":"1956","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib69","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1348-0421.2003.tb03424.x","article-title":"Improved recovery of rabies virus from cloned cDNA using a vaccinia virus-free reverse genetics system","volume":"47","author":"Ito","year":"2003","journal-title":"Microbiology and Immunology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib70","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cardfail.2009.01.013","article-title":"Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1\/2 clinical trial","volume":"15","author":"Jaski","year":"2009","journal-title":"Journal of Cardiac Failure"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib71","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","article-title":"Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure","volume":"124","author":"Jessup","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib72","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2005-12-5115","article-title":"Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib73","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2217\/imt.15.35","article-title":"Talimogene laherparevec (T-VEC) for the treatment of advanced melanoma","volume":"7","author":"Johnson","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib74","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of LentiGlobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib75","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","article-title":"Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial","volume":"369","author":"Kaplitt","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib76","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","article-title":"Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma","volume":"17","author":"Kaufman","year":"2010","journal-title":"Annals of Surgical Oncology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib77","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/83324","article-title":"Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics","volume":"7","author":"Kay","year":"2001","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib78","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1073\/pnas.91.6.2353","article-title":"In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs","volume":"91","author":"Kay","year":"1994","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib79","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1128\/JVI.72.7.5967-5977.1998","article-title":"Encapsidation of the flavivirus Kunjin replicon RNA by using a complementation system providing Kunjin virus structural proteins in trans","volume":"72","author":"Khromykh","year":"1998","journal-title":"Journal of Virology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib80","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-211-78205-7_17","article-title":"AAV-GAD gene for rat models of neuropathic pain and Parkinson\u2019s disease","volume":"101","author":"Kim","year":"2008","journal-title":"Acta Neurochirurgica. Supplement"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib81","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","article-title":"Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency","volume":"384","author":"Kohn","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib82","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jaci.2018.08.024","article-title":"Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency","volume":"143","author":"Kohn","year":"2019","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib83","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.290.5492.767","article-title":"Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate model of Parkinson\u2019s disease","volume":"290","author":"Kordower","year":"2000","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib84","first-page":"161","article-title":"Poxviruses as vectors for cancer immunotherapy","volume":"6","author":"Kwak","year":"2003","journal-title":"Current Opinion in Drug Discovery & Development"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib85","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2019-128482","article-title":"Northstar-3: Interim results from a phase 3 study evaluating lentiglobin gene therapy in patients with transfusion-dependent \u03b2-thalassemia and either a \u03b20 or IVS-I-110 mutation at both alleles of the HBB gene","volume":"134","author":"Lal","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib86","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijid.2016.02.722","article-title":"Engineering of measles virus to target cancer cells, an attempt","volume":"45","author":"Lal","year":"2016","journal-title":"International Journal of Infectious Diseases"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib87","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/ijc.30813","article-title":"Oncolytic maraba virus MG1 as a treatment for sarcoma","volume":"141","author":"Le Boeuf","year":"2017","journal-title":"International Journal of Cancer. Journal International du Cancer"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib88","doi-asserted-by":"crossref","first-page":"12730","DOI":"10.1021\/acs.chemrev.6b00125","article-title":"Retroviral DNA integration","volume":"116","author":"Lesbats","year":"2016","journal-title":"Chemical Reviews"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib89","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/1743-422X-10-241","article-title":"Micro-RNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small lung cancer cells","volume":"10","author":"Li","year":"2013","journal-title":"Virology Journal"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib90","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ymthe.2020.09.001","article-title":"In vivo HSC gene therapy using a bi-modular HDAd5\/35++ vector cures sickle cell disease in a mouse model","volume":"29","author":"Li","year":"2021","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib91","first-page":"1356","article-title":"A new generation of animal cell expression vectors based on the Semliki Forest virus replicon","volume":"9","author":"Liljestr\u00f6m","year":"1991","journal-title":"Biotechnology (Reading, Mass.)"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib92","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1089\/10430340260355365","article-title":"Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer","volume":"13","author":"Limberis","year":"2002","journal-title":"Human Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib93","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering CRISPR: A review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Delivery"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib94","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood-2005-10-4114","article-title":"Tumor vascular targeting therapy with viral vectors","volume":"107","author":"Liu","year":"2006","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib95","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19: An interim analysis of a randomised controlled phase 3 in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib96","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood.V79.5.1225.1225","article-title":"Hemophilia B caused by five different nondeletion mutations in the protease domain of factor IX","volume":"79","author":"Ludwig","year":"1992","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib97","series-title":"Novel approaches and strategies for biologics, vaccines and cancer therapies","first-page":"15","article-title":"New era in gene therapy","author":"Lundstrom","year":"2015"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib98","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/v13020317","article-title":"Viral vectors for COVID-19 vaccine development","volume":"13","author":"Lundstrom","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib99","doi-asserted-by":"crossref","first-page":"15622","DOI":"10.3390\/ijms232415622","article-title":"Therapeutic applications for oncolytic self-replicating RNA viruses","volume":"23","author":"Lundstrom","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2174\/1566523222666220921112753","article-title":"Gene therapy cargoes based on viral vector delivery","volume":"23","author":"Lundstrom","year":"2023","journal-title":"Current Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib101","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3390\/v15030698","article-title":"Viral vectors in gene therapy: Where do we stand in 2023?","volume":"15","author":"Lundstrom","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib102","series-title":"Comprehensive hematology and stem cell research","article-title":"Gene therapy in hematology","author":"Lundstrom","year":"2023"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib103","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1525-0016(02)00056-4","article-title":"Novel Semliki Forest virus vectors with reduced toxicity and temperature-sensitivity for long-term enhancement of transgene expression","volume":"7","author":"Lundstrom","year":"2003","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib104","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/mt.2010.258","article-title":"Preclinical safety evaluation of AAV2-sFFLT101- a gene therapy for age-related macular degeneration","volume":"19","author":"Maclachlan","year":"2011","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib105","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ymthe.2020.11.029","article-title":"Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy","volume":"29","author":"Maguire","year":"2021","journal-title":"Molecular Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib106","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00280-017-3260-6","article-title":"A phase II study of REOLYSIN\u00ae (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma","volume":"79","author":"Mahalingam","year":"2017","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib107","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41591-018-0301-6","article-title":"Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ss-thalassemia","volume":"25","author":"Marktel","year":"2019","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib108","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00439-013-1288-1","article-title":"Silencing human genetic diseases with oligonucleotide-based therapies","volume":"132","author":"Martinez","year":"2013","journal-title":"Human Genetics"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib109","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","article-title":"Self-complimentary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis","volume":"8","author":"McCarty","year":"2001","journal-title":"Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib110","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib111","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74. MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib112","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/gt.2017.71","article-title":"AAV5\u2013miHTT gene therapy demonstrates suppression of huntingtin aggregation and neuronal dysfunction in a rat model of Huntington\u2019s disease","volume":"24","author":"Miniarikova","year":"2017","journal-title":"Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib113","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1073\/pnas.97.2.793","article-title":"Adenoviral gene transfer of SERCa2a improves left-ventricular function in aortic-banded rats in transition to heart failure","volume":"97","author":"Miyamoto","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.605380","article-title":"Strategies for targeting gene therapy in cancer cells with tumor-specific promoters","volume":"10","author":"Monta\u00f1o-Samaniego","year":"2020","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib115","first-page":"1","article-title":"Clinical trials of self-replicating RNA-based cancer vaccines","volume":"10","author":"Morse","year":"2023","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib116","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/pros.20857","article-title":"Engineered measles virus as a novel oncolytic therapy against prostate cancer","volume":"69","author":"Msaouel","year":"2009","journal-title":"The Prostate"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib117","first-page":"1","article-title":"Gene therapy for hemophilia","author":"Nathwani","year":"2019","journal-title":"Hematology\/The Education Program of the American Society of Hematology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib118","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long\u2010term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib119","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long\u2010term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nature Biotechnology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib120","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/mt.2008.61","article-title":"Lentiviral vector\u2013mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats","volume":"16","author":"Niwano","year":"2008","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib121","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cell.2020.03.011","article-title":"A vaccine against Ebola virus","volume":"181","author":"Ollmann Saphire","year":"2020","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib122","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/humc.2018.081","article-title":"Long\u2010term follow\u2010up of a phase I\/II of ProSavin, a lentiviral vector gene therapy for Parkinson\u2019s disease","volume":"29","author":"Palfi","year":"2018","journal-title":"Human Gene Therapy. Clinical Development"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib123","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","article-title":"Long\u2010term safety and tolerability of ProSavin, a lentiviral vector\u2010based gene therapy for Parkinson\u2019s disease: A dose escalation, open\u2010label, phase 1\/2 trial","volume":"383","author":"Palfi","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib124","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow\u2010up of AAV5\u2013hFVIII\u2010SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib125","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI41615","article-title":"CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy","volume":"120","author":"Passini","year":"2010","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib126","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41434-019-0085-4","article-title":"AAV9 vector: A novel modality in gene therapy for spinal muscular atrophy","volume":"26","author":"Pattali","year":"2019","journal-title":"Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib127","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1126\/science.1065806","article-title":"Correction of sickle cell disease in transgenic mouse models by gene therapy","volume":"294","author":"Pawliuk","year":"2001","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2023.06.001","article-title":"A trans-amplifying RNA simplified to essential elements is highly replicative and robustly immunogenic in mice","author":"Perkovic","year":"2023","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib129","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1517\/14712598.6.2.135","article-title":"Kunjin virus replicons: An RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications","volume":"6","author":"Pijlman","year":"2006","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib130","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1073\/pnas.96.8.4598","article-title":"Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors","volume":"96","author":"Polo","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib131","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCov\u201019 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled phase 2\/3 trial","volume":"336","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib132","series-title":"Novel approaches and strategies for biologics, vaccines and vancer therapies","first-page":"365","article-title":"Cancer vaccines","author":"Ramirez-Montagut","year":"2015"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib133","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1021\/bc200422w","article-title":"Lipid conjugated oligonucleotides: A useful strategy for delivery","volume":"23","author":"Raouane","year":"2012","journal-title":"Bioconjugate Chemistry"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib134","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: Talimigene laherparevec (T\u2010VEC), a first\u2010in\u2010class intratumoral oncolytic viral therapy","volume":"4","author":"Rehman","year":"2016","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib135","first-page":"147","article-title":"Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki Forest virus vector carrying the human interleukin-12 gene\u2014a phase I\/II clinical protocol","volume":"64","author":"Ren","year":"2003","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib136","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib137","first-page":"12","article-title":"Manufacturing of recombinant adeno-associated viruses using mammalian expression platforms","author":"Robert","year":"2017","journal-title":"Biotechnology Journal"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib138","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/JHD-200002","article-title":"Huntington\u2019s disease clinical trials corner: April 2020","volume":"9","author":"Rodrigues","year":"2020","journal-title":"Journal of Huntington\u2019s Disease"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib139","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1874467210801010013","article-title":"Gene therapy: The first approved gene-based medicines, molecular mechanisms and clinical indications","volume":"1","author":"R\u00e4ty","year":"2008","journal-title":"Current Molecular Pharmacology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib140","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ymthe.2020.11.029","article-title":"Clinical perspective: Treating RPE65\u2013associated retinal dystrophy","volume":"29","author":"Russell","year":"2021","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib141","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1006\/mthe.2001.0294","article-title":"Improved helper virus\u2010free packaging system for HSV amplicon vectors using an ICP27\u2013deleted, oversized HSV\u20101 DNA in a bacterial artificial chromosome","volume":"3","author":"Saeki","year":"2001","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib142","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S0006-291X(02)00362-5","article-title":"Micro\u2010 dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene","volume":"293","author":"Sakamoto","year":"2002","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib143","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","article-title":"AAV\u2010mediated gene therapy for research and therapeutic purposes","volume":"1","author":"Samulski","year":"2014","journal-title":"Annual Review of Virology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib144","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1182\/blood-2003-08-2954","article-title":"Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype","volume":"103","author":"Sarkar","year":"2004","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib145","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1046\/j.1538-7836.2003.00096.x","article-title":"A single adeno-associated virus (AAV)\u2010murine factor FVIII","volume":"1","author":"Sarkar","year":"2003","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib146","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hon.2591","article-title":"CAR-T cell therapy: Full speed ahead","volume":"37","author":"Sermer","year":"2019","journal-title":"Hematological Oncology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib147","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1158\/1078-0432.CCR-0690-3","article-title":"Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21","volume":"10","author":"Shafren","year":"2014","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib148","doi-asserted-by":"crossref","first-page":"11592","DOI":"10.1038\/s41598-019-48078-4","article-title":"In Utero Gene Therapy (IUGT) using GLOBE lentiviral vector phenotypically corrects the heterozygous humanised mouse model and its progress can be monitored using MRI techniques","volume":"9","author":"Shangaris","year":"2019","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib149","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1089\/10430340050083243","article-title":"Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino acid decarboxylase, and GTP cyclohydrolase I for gene therapy for Parkinson\u2019s disease","volume":"11","author":"Shen","year":"2000","journal-title":"Human Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib150","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1538-7836.2007.02346.x","article-title":"Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A","volume":"5","author":"Shi","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib151","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s005950170093","article-title":"Preclinical study of adenoviral p53 gene therapy for esophageal cancer","volume":"3","author":"Shimada","year":"2001","journal-title":"Surgery Today"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib152","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.vaccine.2012.11.096","article-title":"A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer","volume":"31","author":"Slovin","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib153","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.gt.3302156","article-title":"Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice","volume":"11","author":"Song","year":"2004","journal-title":"Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib154","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jama.2021.3645","article-title":"Immunogenicity of the Ad26.COV2.S vaccine for COVID\u201019","volume":"325","author":"Stephenson","year":"2021","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib155","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/mr.58.3.491-562.1994","article-title":"The alphaviruses; gene expression, replication and evolution","volume":"58","author":"Strauss","year":"1994","journal-title":"Microbiological Reviews"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib156","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11010-020-03834-3","article-title":"Gene therapy: A double-edged sword with great powers","volume":"474","author":"Tang","year":"2020","journal-title":"Molecular and Cellular Biochemistry"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib157","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00262-019-02360-6","article-title":"Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy","volume":"68","author":"Tarone","year":"2019","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib158","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/mthe.2000.0130","article-title":"Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor","volume":"2","author":"Toda","year":"2000","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib159","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.omtm.2017.06.007","article-title":"Generation of a Vero\u2010based packaging cell line to produce SV40 gene delivery vectors for use in clinical gene therapy studies","volume":"6","author":"Toscano","year":"2017","journal-title":"Molecular Therapy - Methods and Clinical Development"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib160","first-page":"1786","article-title":"Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer","volume":"143","author":"Urbiola","year":"2018","journal-title":"International Journal of\u00a0Cancer. Journal International du Cancer"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib161","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1016\/j.ymthe.2022.09.020","article-title":"First conditional marketing authorization approval in the European Union for hemophilia \u201cA\u201d gene therapy","volume":"30","author":"VandenDriessche","year":"2022","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib162","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1093\/hmg\/ddv451","article-title":"Progress and challenges in viral vector manufacturing","volume":"25","author":"Van der Loo","year":"2016","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib163","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.ophtha.2017.12.036","article-title":"Safety of rAAV2\/2\u2013ND4 gene therapy","volume":"125","author":"Vignal","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib164","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/gyno.1998.5010","article-title":"In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer","volume":"69","author":"von Grueningen","year":"1998","journal-title":"Gynecologic Oncology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib165","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","article-title":"Opportunities and challenges in the delivery of mRNA-based vaccines","volume":"12","author":"Wadwha","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib166","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/1566523054065048","article-title":"AAV\u2010mediated gene transfer for treatment of hemophilia","volume":"5","author":"Wang","year":"2005","journal-title":"Current Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib167","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1021\/acs.molpharmaceut.8b01046","article-title":"Liposome encapsulation of oncolytic virus M1 To reduce immunogenicity and immune clearance in vivo","volume":"16","author":"Wang","year":"2019","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib168","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/mt.2012.157","article-title":"AAV vectors containing rDNA homology increased chromosomal integration and transgene persistence","volume":"20","author":"Wang","year":"2012","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib169","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/mt.2012.111","article-title":"Successful regional delivery and long\u2010term expression of a dystrophin gene in canine muscular dystrophy: A preclinical model for human therapies","volume":"20","author":"Wang","year":"2012","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib170","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1159\/000475909","article-title":"Engineering the rapid adenovirus production and amplification (RAPA) cell line to expedite the generation of recombinant adenoviruses","volume":"41","author":"Wei","year":"2017","journal-title":"Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib171","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/sj.mt.6300355","article-title":"Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose","volume":"16","author":"Wu","year":"2008","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.micres.2022.126993","article-title":"Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies","volume":"258","author":"Xiang","year":"2022","journal-title":"Microbiological Research"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib173","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The first approved gene therapy product for cancer ad\u2010p53 (Gendicine): 12 years in the clinic","volume":"29","author":"Zhang","year":"2018","journal-title":"Human Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib174","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1038\/s41388-021-01869-4","article-title":"Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC","volume":"40","author":"Zhang","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib175","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3892\/or.2012.2109","article-title":"Live attenuated measles virus vaccine induces apoptosis and promotes tumor regression in lung cancer","volume":"29","author":"Zhao","year":"2013","journal-title":"Oncology Reports"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib176","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/CIRCRESAHA.113.302421","article-title":"Long\u2010term effects of AAV1\/SERCA2a gene transfer in patients with severe heart failure: Analysis of recurrent cardiovascular events and mortality","volume":"114","author":"Zsebo","year":"2014","journal-title":"Circulation Research"},{"key":"10.1016\/bs.ircmb.2023.05.005_bib177","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type\u20105\u2013vectored COVID\u201019 vaccine in healthy adults aged 18 years or older: A randomised, double\u2010blind, placebo\u2010controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"}],"container-title":["International Review of Cell and Molecular Biology","Viral Vectors in Cancer Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644823000679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644823000679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T15:33:12Z","timestamp":1753457592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644823000679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780443192494"],"references-count":177,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2023.05.005","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}